In patients with liver cirrhosis who have survived a variceal haemorrhage, the risk of rebleeding is substantial. Managing this population requires a dedicated secondary prophylaxis strategy rather than acute haemorrhage control alone.
The recommended first-line approach in this setting combines a pharmacological agent with an endoscopic procedure. Combination therapy has demonstrated a superior reduction in rebleeding risk compared with either intervention used in isolation.